Nicotinamide Riboside
Best for
Raise cellular NAD+ levels
Likely strong benefit · 1000 mg/day for 4–26 weeks · 6 studies , n=141
10 papers · 1 claim · 33 outcomes scored · 1 positive
Outcomes
What nicotinamide riboside actually does, by outcome
Each row is one outcome with effect size, evidence base, the dose that worked in trials, and time to first effect. Magnitude tiers come from native-unit MCID where available, Cohen's d otherwise.
| Outcome | Effect | Evidence | Dose | Weeks | Rank |
|---|---|---|---|---|---|
| Raise cellular NAD+ levels Likely strong benefit | | 6 RCTs n=141 | 1000 mg | 4–26 wk | #2/2 |
Recommended Nicotinamide Riboside products
Real products that dose Nicotinamide Riboside where the research does, in a clean formulation, from brands we've audited. We only list ones we'd stand behind.
-
Thorne
NiaCel 400
Well dosed 830 mg/day B formulaBrand audit 79/100
-
ChromaDex
Tru Niagen 300 mg
Well dosed 900 mg/day B formula -
Renue By Science
NR 1000
Well dosed 1,000 mg/day B formula
Chosen for adequate Nicotinamide Riboside dosing vs. the studied range, a clean formulation (grade A–C), and independent brand-quality audits. Not sponsored.
Risk profile
Adverse events and known drug interactions
Safety events
Sources
- 1. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. (2018) ↑
- 2. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. (2020) ↑
- 3. The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. (2022) ↑
- 4. Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults. (2022) ↑
- 5. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. (2023) ↑
- 6. Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial. (2025) ↑
- 7. Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment. (2025) ↑
- 8. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. (2024) ↑
- 9. Randomized Crossover Clinical Trial of Nicotinamide Riboside and Coenzyme Q10 on Metabolic Health and Mitochondrial Bioenergetics in CKD. (2024) ↑
- 10. A Pilot Trial of Nicotinamide Riboside and Coenzyme Q10 on Inflammation and Oxidative Stress in CKD. (2025) ↑
Generated August 14, 2026
Related